GlassScriptPhysician profile
Arash A Sadeghian
NPI 1447392246
$16,158.65
in general payments reported to CMS, 2019-2025
31 companies · $5,483 in 2025
The $5,483 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,119 · 2020: $1,399 · 2021: $2,074 · 2022: $1,901 · 2023: $1,679 · 2024: $1,504 · 2025: $5,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,594 · Education: $51.50 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,593.83 |
| Education | $51.50 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $4,219.27 | 2024-2025 | Optilight, M22 |
| Sun Pharmaceutical Industries INC. | $1,699.81 | 2020-2025 | Cequa, Bromsite, Xelpros |
| Bausch & Lomb Americas INC. | $1,255.67 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,000.84 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $715.64 | 2019-2021 | |
| Harrow Eye, LLC | $662.37 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $645.82 | 2019-2023 | |
| Oyster Point Pharma, INC. | $602.36 | 2022-2023 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $558.01 | 2020-2023 | Flarex |
| Alcon Vision LLC | $540.17 | 2020-2025 | Rocklatan, Tryptyr, Dailies |
| Coopervision INC. | $536.57 | 2019-2023 | Myday Contact Lens |
| Optovue, INC. | $500.00 | 2019 | |
| Abbvie INC. | $432.88 | 2022-2025 | |
| Glaukos Corporation | $429.10 | 2020-2025 | Ce-Marked Kxla System, Istent Infinite, Idosetr |
| Allergan, INC. | $401.63 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $332.49 | 2021-2022 | |
| Shire North American Group INC | $304.12 | 2019 | |
| Sight Sciences, INC. | $272.73 | 2020-2022 | |
| Biotissue Holdings INC. | $266.96 | 2019-2024 | |
| Dompe US, INC. | $158.66 | 2021-2025 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $134.23 | 2019 | |
| Optos, INC. | $107.22 | 2019 | |
| Topcon Healthcare, INC. | $90.43 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $56.91 | 2024-2025 | Xdemvy |
| Ascendis Pharma Endocrinology INC | $51.50 | 2025 | |
| Abb Con-Cise Optical Group LLC | $46.14 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $39.41 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $37.95 | 2025 | |
| Amgen INC. | $29.21 | 2024 | Tepezza |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Ani Pharmaceuticals, INC. | $13.31 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arash Sadeghian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.